57 related articles for article (PubMed ID: 23379748)
1. Effect of glacial acetic acid pre-treatment of cervical liquid-based cytology specimens on the molecular detection of human papillomavirus.
Moore C; Cuschieri K; McQueen F; Duvall E; Graham C; Cubie HA
Cytopathology; 2013 Oct; 24(5):314-20. PubMed ID: 23379748
[TBL] [Abstract][Full Text] [Related]
2. Stability of human papillomavirus (HPV) in cervical ThinPrep specimens previously lysed with glacial acetic acid: effect on cobas 4800 HPV test performance.
McMenamin M; McKenna M
Cancer Cytopathol; 2014 Apr; 122(4):250-6. PubMed ID: 24302639
[TBL] [Abstract][Full Text] [Related]
3. Effect of glacial acetic acid treatment of cervical ThinPrep specimens on HPV DNA detection with the cobas 4800 HPV test.
McMenamin M; McKenna M
Cytopathology; 2013 Oct; 24(5):321-6. PubMed ID: 23445358
[TBL] [Abstract][Full Text] [Related]
4. Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.
Moore C; Duvall E; Braby E; Reid G; Docherty E; Grieve L; Cubie H; Graham C; Cuschieri K
J Clin Virol; 2016 Jun; 79():32-35. PubMed ID: 27060653
[TBL] [Abstract][Full Text] [Related]
5. Precancerous cervical lesions and HPV genotypes identified in previously unsatisfactory cervical smear tests after inexpensive glacial acetic acid processing.
Risley C; Geisinger KR; Robinson JC; Stewart MW; Zhang L; Alexander R; Raab SS
Int J Gynaecol Obstet; 2019 Jan; 144(1):85-89. PubMed ID: 30362108
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China.
Zhao FH; Hu SY; Bian JJ; Liu B; Peck RB; Bao YP; Pan QJ; Frappart L; Sellors J; Qiao YL
Cancer Cytopathol; 2011 Dec; 119(6):387-94. PubMed ID: 21774094
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of reprocessing unsatisfactory cervicovaginal ThinPrep specimens with and without glacial acetic acid: effect on Hybrid Capture II human papillomavirus testing and clinical follow-up.
Agoff SN; Dean T; Nixon BK; Ingalls-Severn K; Rinker L; Grieco VS
Am J Clin Pathol; 2002 Nov; 118(5):727-32. PubMed ID: 12428793
[TBL] [Abstract][Full Text] [Related]
8. Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay.
Munson E; Schroeder ER; Ross KC; Yauck C; Bieganski T; Amrhein RD; Napierala M; Harkins AL
J Clin Microbiol; 2014 May; 52(5):1448-52. PubMed ID: 24554753
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
10. Reflex high-risk human papillomavirus DNA testing (Hybrid Capture 2) of bloody ThinPrep specimens with atypical squamous cells of undetermined significance interpretation: does pretreatment with acetic acid affect test performance?
Feng J; Husain M
Cancer; 2005 Dec; 105(6):452-6. PubMed ID: 16080178
[TBL] [Abstract][Full Text] [Related]
11. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
Cubie HA; Moore C; Waller M; Moss S;
J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
[TBL] [Abstract][Full Text] [Related]
12. Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens.
Iftner T; Wang L; Iftner A; Holz B; Haedicke-Jarboui J; Iftner N; von Wasielewski R; Martus P; Boehmer G
BMC Infect Dis; 2016 Nov; 16(1):672. PubMed ID: 27835974
[TBL] [Abstract][Full Text] [Related]
13. Maximizing the adequacy of Hologic(®) Cervista(®) HPV HR results on ThinPrep(®) Pap samples treated with glacial acetic acid.
Mahajan A; Kucher E; Hoefle W; Engelhardt S; Accola M; Barasch S; Rehrauer W; Selvaggi SM
Diagn Cytopathol; 2016 Mar; 44(3):215-9. PubMed ID: 26779984
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus detection: verification with cervical cytology.
Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
[TBL] [Abstract][Full Text] [Related]
15. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
17. [HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].
Burroni E; Sani C; Bisanzi S; Ocello C
Epidemiol Prev; 2016; 40(3-4):164-70. PubMed ID: 27436249
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
[TBL] [Abstract][Full Text] [Related]
19. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
